Cell Expansion Market Size, Share, Growth Analysis, By Product(Consumables, Culture Flasks & Accessories, Instruments), By Cell Type(Mammalian, Microbial, Others), By Region - Industry Forecast 2024-2031

The global cell expression market is highly competitive and consists of several key players. These players engage in strategies such as collaborations, partnerships, mergers and acquisitions, and product launches to gain a competitive edge.

Cell Expansion Market Top Player’s Company Profiles

• Thermo Fisher Scientific Inc. (United States)

• Merck KGaA (Germany)

• Lonza Group Ltd. (Switzerland)

• GE Healthcare (United States)

• Sartorius AG (Germany)

• Promega Corporation (United States)

• Agilent Technologies, Inc. (United States)

• Bio-Rad Laboratories, Inc. (United States)

• Eppendorf AG (Germany)

• Takara Bio Inc. (Japan)

• GenScript Biotech Corporation (China)

• CellGenix GmbH (Germany)

• BD Biosciences (United States)

• Novasep Holding S.A.S. (France)

• OriGene Technologies, Inc. (United States)

• Lonza Biologics Plc (United Kingdom)

• Danaher Corporation (United States)

• Wuxi AppTec Co., Ltd. (China)

• Charles River Laboratories International, Inc. (United States)

• Miltenyi Biotec GmbH (Germany)

• New England Biolabs, Inc. (United States)

• Qiagen N.V. (Netherlands)

Cell Expansion Market Recent Development

• In March 2024, CellRev, in partnership with Getinge, launched a breakthrough adherent cell expansion platform, Livit ACE. Designed to eliminate many of the limitations and inefficiencies associated with adherent cell culture, Livit ACE reduces costs, enhances productivity and accelerates development times. 
• In February 2024, Multiply Labs and Thermo Fisher Scientific expanded partnership to automate cell expansion and separation in cell therapy manufacturing. 
• In September 2023, BioCentriq, Inc. and panCELLa, a Pluristyx Company, signed a research agreement to evaluate the ability of panCELLa's genetically engineered, induced Pluripotent Stem Cell (iPSC)-derived, feeder cells to activate and positively impact the expansion rate, total yield, and potency of manufactured NK cells. 
• In April 2023, Abbott announced the launch of its new Freestyle Libre 3 continuous glucose monitoring (CGM) system. The Freestyle Libre 3 is a small, wearable sensor that measures blood glucose levels every minute and sends the data to a smartphone app. The system is designed to be more user-friendly and affordable than other CGM systems on the market. 
• In March 2023, Medtronic announced the launch of its new MiniMed 780G hybrid closed-loop insulin delivery system. The MiniMed 780G system is a combination of an insulin pump and a CGM system that automatically adjusts insulin delivery based on blood glucose levels. The system is designed to help people with type 1 diabetes achieve better glycemic control.